P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, ...

Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...

Adam Friedman, MD: Hello, and welcome to Medscape Care Cues. I'm Dr Adam Friedman and I'm joined by my good friend and colleague, Dr Shawn Kwatra. Welcome, Shawn. Shawn G. Kwatra, MD: Thanks so ...

Opens in a new tab or window Chronic urticaria (CU) is a common skin condition characterized by the spontaneous development of angioedema. A person with CU may experience chronic spontaneous ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease ...

Jasper Therapeutics, Inc. (NASDAQ:JSPR) reported preliminary data from the ongoing BEACON Phase 1b/2a study of subcutaneous ...

Analyst Silvan Tuerkcan of JMP Securities reiterated a Buy rating on Allakos (ALLK – Research Report), with a price target of $3.00.Stay Ahead ...

Novartis' big-selling IgE inhibitor Xolair has been a mainstay of treatment for refractory chronic spontaneous urticaria (CSU) for many years, but its efforts to find a successor have seen some ...

Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profileMean change in UAS7 ...

InflaRx has commenced a Phase 2a study for INF904 in chronic spontaneous urticaria and hidradenitis suppurativa, dosing its first patient. InflaRx N.V. has announced the initiation of a Phase 2a ...

Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts, indicating potential effectiveness of briquilimab in treating chronic spontaneous urticaria (CSU).